Jennifer L Cultrera1, Samir M Dalia. 1. Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA. Jennifer.Cultrera@moffitt.org
Abstract
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common histology of non-Hodgkin lymphoma, representing 25% to 35% of new cases annually. The incidence of DLBCL has doubled in the past decades, highlighting the need for more effective treatment regimens. METHODS: This article reviews the current protocols applicable to this aggressive lymphoma and discusses ongoing research that is focusing on molecular diagnostics, prognostic factors have also been defined for DLBCL. RESULTS: Patients with DLBCL vary in clinical presentation, prognosis, and response to current therapies. While current therapy in the rituximab era has led to improved outcomes with reduced toxicity, novel treatment approaches for localized, advanced, and relapsed/refractory DLBCL are being pursued in clinical trials. Several studies have shown promise, such as trials involving proteasome inhibitors, lenalidomide, and antibody drug conjugates. CONCLUSIONS: Recent discoveries in the spectrum of care for patients with DLBCL have prompted a renaissance for personalized cancer medicine and molecularly targeted therapy. Potential targets and novel drug combinations are undergoing continued study in the hope of achieving successful and personalized care of this disease.
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common histology of non-Hodgkin lymphoma, representing 25% to 35% of new cases annually. The incidence of DLBCL has doubled in the past decades, highlighting the need for more effective treatment regimens. METHODS: This article reviews the current protocols applicable to this aggressive lymphoma and discusses ongoing research that is focusing on molecular diagnostics, prognostic factors have also been defined for DLBCL. RESULTS:Patients with DLBCL vary in clinical presentation, prognosis, and response to current therapies. While current therapy in the rituximab era has led to improved outcomes with reduced toxicity, novel treatment approaches for localized, advanced, and relapsed/refractory DLBCL are being pursued in clinical trials. Several studies have shown promise, such as trials involving proteasome inhibitors, lenalidomide, and antibody drug conjugates. CONCLUSIONS: Recent discoveries in the spectrum of care for patients with DLBCL have prompted a renaissance for personalized cancer medicine and molecularly targeted therapy. Potential targets and novel drug combinations are undergoing continued study in the hope of achieving successful and personalized care of this disease.
Authors: Suzanne Murray; Kevin L Obholz; Andrew D Bowser; Jim Mortimer; Patrice Lazure; Eric Peterson; James O Armitage; B Douglas Smith Journal: J Community Support Oncol Date: 2014-09
Authors: Chi Young Ok; Jiayu Chen; Zijun Y Xu-Monette; Alexandar Tzankov; Ganiraju C Manyam; Ling Li; Carlo Visco; Santiago Montes-Moreno; Karen Dybkær; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Xiaoying Zhao; Maurilio Ponzoni; Andrés J M Ferreri; Francesco Bertoni; John P Farnen; Michael B Møller; Miguel A Piris; Jane N Winter; L Jeffrey Medeiros; Ken H Young Journal: Clin Cancer Res Date: 2014-08-14 Impact factor: 12.531
Authors: M K McKenna; B W Gachuki; S S Alhakeem; K N Oben; V M Rangnekar; R C Gupta; S Bondada Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742
Authors: Fritz Offner; Olga Samoilova; Evgenii Osmanov; Hyeon-Seok Eom; Max S Topp; João Raposo; Viacheslav Pavlov; Deborah Ricci; Shalini Chaturvedi; Eugene Zhu; Helgi van de Velde; Christopher Enny; Aleksandra Rizo; Burhan Ferhanoglu Journal: Blood Date: 2015-07-31 Impact factor: 22.113